Analysis: SAHPRA decision on ivermectin shifts heavy responsibility to doctors
In allowing section 21 applications as part of a controlled compassionate access programme, SAHPRA has essentially shifted the responsibility for deciding whether the anti-parasitic ivermectin is safe and effective enough to be used in the treatment of COVID-19 to doctors. This places an enormous responsibility on doctors, writes Adele Baleta.
